Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.08 which represents a slight increase of $0.11 or 1.58% from the prior close of $6.97. The stock opened at $7.02 and ...

TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $9.00. The ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...